Title: A Case Report of Endometrial Carcinoma in a Patient Treated with Tamoxifene and Letrozole for Carcinoma Breast
Authors: Avinash Ranjan, Mayank Gautam, S.N. Prasad
DOI: https://dx.doi.org/10.18535/jmscr/v9i3.09
Abstract
The risk of endometrial cancer and breast cancer are increased by higher endogenous estrogen levels. Tamoxifene is a selective estrogen receptor modulater used for treatment and prevention of estrogen receptor positive breast cancer. However it increases the risk of endometrial cancer. Letrozole an aromatase inhibitor reduces breast cancer incidence but their influence on endometrial cancer is uncertain.
Keywords: Endometrial cancer, Tamoxifene, Breast cancer, Letrozole, Aromatase inhibitor.
References
- Killackey, M.A.; Hakes, T.B.; Pierce, V.K. Endometrial adenocarcinoma in breast cancer patients receiving antiestrogens. Cancer Treat. Rep. 1985, 69, 237–238. [PubMed]
- Fisher, B.; Costantino, J.P.; Redmond, C.K.; Fisher, E.R.; Wickerham, D.L.; Cronin, W.M. Endometrial cancer in tamoxifen-treated breast cancer patients: Findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J. Natl. Cancer Inst. 1994, 86, 527–537. [CrossRef)
- Chlebowski, R.T.; Schottinger, J.E.; Shi, J.; Chung, J.; Haque, R. Aromatase inhibitors, tamoxifen, and endometrial cancer in breast cancer survivors. Cancer 2015, 121, 2147–2155. [CrossRef] [PubMed]
- Davies, C.; Pan, H.; Godwin, J.; Gray, R.; Arriagada, R.; Raina, V.; Abraham, M.; Medeiros Alencar, V.H.; Badran, A.; Bonfill, X.; et al. Adjuvant Tamoxifen: Longer Against Shorter Collaborative, G. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 2013, 381, 805–816. [CrossRef]
- Lee, M.; Piao, J.; Jeon, M.J. Risk Factors Associated with Endometrial Pathology in Premenopausal Breast Cancer Patients Treated with Tamoxifen. Yonsei Med. J. 2020, 61, 317–322. [CrossRef] [PubMed]
- Early Breast Cancer Trialists’ Collaborative Group. Aromatase inhibitors versus tamoxifen in early breast cancer: Patient-level meta-analysis of the randomised trials. Lancet 2015, 386, 1341–1352. [CrossRef]